Resveratrol and cancer treatment: Is hormesis a yet unsolved matter?

Current Pharmaceutical Design

Volumn 19, Issue 30, 2013, Pages 5384-5393

  Borriello, Adriana ^a   Bencivenga, Debora ^a   Caldarelli, Ilaria ^a   Tramontano, Annunziata ^a   Borgia, Alessia ^a   Pirozzi, Anna Virginia Adriana ^a   Oliva, Adriana ^a   Della Ragione, Fulvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biphasic effects; Cancer treatment; Hormesis; Hormetic effects; Plant molecules; Resveratrol

Indexed keywords

DRUG METABOLITE; RESVERATROL; RESVERATROL 3 O GLUCURONIDE; RESVERATROL 3 O SULFATE; RESVERATROL 4 O GLUCURONIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; GENE EXPRESSION REGULATION; HEADACHE; HORMESIS; HUMAN; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HORMESIS; HUMANS; NEOPLASMS; STILBENES;

EID: 84881365302     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319300007     Document Type: Review

References (147)

1. Takaoka M. Resveratrol, a new phenolic compound, from Veratrum grandiflorum. Nippon Kagaku Kaishi 1939; 60: 1090-100.
2. Shakibaei M, Harikumar KB and Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009; 53: 115-28.
3. Langcake P and Pryce RJ. The production of resveratrol by Vitisvinifera and other members of the Vitaceae as a response to infection and injury. Physiol Plant Pathol 1976; 9: 77-86.
4. Jeandet P, Bessis R, and Gautheron B. The Production of Resvera-trol (3,5,4'-trihydroxystilbene) by Grape Berries in Different Developmental Stages. Am J Enol Vitic 1991; 42: 41.
5. Roggero JP, and Garciaparrilla C. Effects of ultraviolet irradiationon resveratrol and changes in resveratrol and various of its derivatives in the skins of ripening grapes. Sci Aliments 1995; 15: 411-22.
6. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activityof resveratrol, a natural product derived from grapes. Science 1997; 275: 218-22.
7. Sbaghi M, Jeandet P, Faivre B, Bessis R, and Fournioux, JC. De-velopment of methods, using phytoalexin (resveratrol) assessment as a selection criterion to screen grapevine in vitro cultures for resistance to grey mould (Botrytis cinerea). Euphytica 1995; 86: 41-6.
8. Stark-Lorenzen P, Nelke B, Henssler G, Muhlbach HP, and Thom-zik JE. Transfer of a grapevine stilbene synthase gene to rice (Oryza sativa L). Plant Cell Rep 1997; 16, 668-73.
9. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, and DellaRagione F. Resveratrol: from basic science to the clinic., Cell Cycle 2007; 6: 2495-510.
10. Baur JA, and Sinclair DA. Therapeutic potential of resveratrol: thein vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
11. Della Ragione F, Cucciolla V, Borriello A, et al. Resveratrol arreststhe cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998; 250: 53-8.
12. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleu-kin-1beta-induced activation of the nuclear transcription factor NFkappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 2003; 102: 987-95.
13. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Isorhapontigenin andresveratrol suppress oxLDL-induced proliferation and activation of ERK1/2 mitogen-activated protein kinases of bovine aortic smooth muscle cells. Biochem Pharmacol 2004; 67: 777-85.
14. Pozo-Guisado E, Lorenzo-Benayas MJ, Fernández-Salguero PM. Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer 2004; 109: 167-73.
15. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibitsproliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. 2007; Blood 109: 2293-302.
16. Lee MH, Choi BY, Kundu JK, et al. Resveratrol suppresses growthof human ovarian cancer cells in culture and in a murine xenograft model: eukaryotic elongation factor 1A2 as a potential target. Cancer Res 2009; 69: 7449-58.
17. Chen Q, Ganapathy S, Singh KP, et al. Resveratrol induces growtharrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 2010; 5: e15288.
18. Asou H, Koshizuka K, Kyo T, et al. Resveratrol, a natural productderived from grapes, is a new inducer of differentiation in human myeloid leukemias. Int J Hematol 2002; 75: 528-33.
19. Boissy P, Andersen TL, Abdallah BM, et al. Resveratrol inhibitsmyeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005; 65: 9943-52.
20. Leong CW, Wong CH, Lao SC, et al. Effect of resveratrol on proliferation and differentiation of embryonic cardiomyoblasts. Biochem Biophys Res Commun 2007; 360: 173-80.
21. Yu LJ, Wu ML, Li H, et al. Inhibition of STAT3 expression andsignaling in resveratrol-differentiated medulloblastoma cells. Neoplasia 2008; 10: 736-44.
22. Ko YC, Chang CL, Chien HF, et al. Resveratrol enhances the expression of death receptor Fas/CD95 and induces differentiation and apoptosis in anaplastic large-cell lymphoma cells. Cancer Lett 2011; 309: 46-53.
23. Kaminski J, Lançon A, Aires V, et al. Resveratrol initiates differentiation of mouse skeletal muscle-derived C2C12 myoblasts. Biochem Pharmacol 2012; 84: 1251-9.
24. Manna SK, Mukhopadhyay A, Aggarwal BB Resveratrol sup-presses TNF-induced activation of nuclear transcription factors NFkappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000; 164: 6509-19.
25. Tinhofer I, Bernhard D, Senfter M, et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J 2001; 15: 1613-5.
26. Ahmad KA, Clement MV, Hanif IM, et al. Resveratrol inhibitsdrug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 2004; 64: 1452-9.
27. Opipari AW Jr, Tan L, Boitano AE, et al. Resveratrol-inducedautophagocytosis in ovarian cancer cells. Cancer Res 2004; 64: 696-703.
28. Fulda S, Debatin KM Resveratrol-mediated sensitisation toTRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 2005; 41: 786-98.
29. Lin HY, Tang HY, Keating T, et al. Resveratrol is pro-apoptoticand thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 2008; 29: 62-9.
30. Scarlatti F, Maffei R, Beau I, et al. Role of non-canonical Beclin 1-independent autophagy in cell death induced by resveratrol in human breast cancer cells. Cell Death Differ 2008; 8: 1318-29.
31. Mader I, Wabitsch M, Debatin KM, et al. Identification of a novelproapoptotic function of resveratrol in fat cells: SIRT1independent sensitization to TRAIL-induced apoptosis. FASEB J 2010; 24: 1997-2009.
32. Puissant A, Robert G, Fenouille N, et al. Resveratrol promotesautophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 2010; 70: 1042-52.
33. Puissant A, Auberger P. AMPK and p62/SQSTM1-dependentautophagy mediate Resveratrol-induced cell death in chronic myelogenous leukemia. Autophagy 2010; 6: 655-7.
34. Morselli E, Mariño G, Bennetzen MV, et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol 2011; 192: 615-29.
35. Wu Y, Li X, Zhu JX, et al. Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals 2011; 19: 163-74.
36. Zhang F, Liu J, Shi JS. Anti-inflammatory activities of resveratrolin the brain: role of resveratrol in microglial activation. Eur J Pharmacol 2010; 636: 1-7.
37. Li F, Gong Q, Dong H, et al. Resveratrol, a neuroprotective sup-plement for Alzheimer's disease. Curr Pharm Des 2012; 18: 27-33.
38. Alex D, Leong EC, Zhang ZJ, et al. Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular disrupting effects in zebrafish through the downregulation of VEGFR2 and cell cycle modulation. J Cell Biochem 2010; 109: 339-46.
39. Bråkenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumorgrowth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J 2001; 15: 1798-800.
40. Cao Y, Fu ZD, Wang F, et al. Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J Asian Nat Prod Res 2005; 7: 205-13.
41. Srivastava RK, Unterman TG, Shankar S. FOXO transcriptionfactors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 2010; 337: 201-12.
42. Hanahan D, Weinberg RA. Hallmarks of cancer: the nextgeneration. Cell 2011; 144: 646-74.
43. El-Mowafy AM, White RE. Resveratrol inhibits MAPK activityand nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett 1999; 451: 63-7.
44. Yu R, Hebbar V, Kim DW, et al. Resveratrol inhibits phorbol esterand UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol 2001; 60: 217-24.
45. Banerjee Mustafi S, Chakraborty PK, Raha S. Modulation of Aktand ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70. PLoS One 2010; 5: e8719.
46. She QB, Huang C, Zhang Y, et al. Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 2002; 33: 244-50.
47. Woo JH, Lim JH, Kim YH, et al. Resveratrol inhibits phorbolmyristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004; 23: 1845-53.
48. Holmes-McNary M, Baldwin AS Jr. Chemopreventive propertiesof trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 2000; 60: 3477-83.
49. Kundu JK, Shin YK, Kim SH, et al. Resveratrol inhibits phorbolester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006; 27: 1465-74.
50. Haider UG, Sorescu D, Griendling KK, et al. Resveratrol sup-presses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol Pharmacol 2002; 62: 772-7.
51. Haider UG, Roos TU, Kontaridis MI, et al. Resveratrol inhibitsangiotensin IIand epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2. Mol Pharmacol 2005; 68: 41-8.
52. Wang Y, Romigh T, He X, et al. Resveratrol regulates thePTEN/AKT pathway through androgen receptor dependent and independent mechanisms in prostate cancer cell lines. Hum Mol Genet 2010; 19: 4319-29.
53. Stewart JR, Christman KL, O'Brian CA. Effects of resveratrol onthe autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol 2000; 60: 1355-9.
54. Shih A, Zhang S, Cao HJ, et al. Inhibitory effect of epidermalgrowth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol Cancer Ther 2004; 3: 1355-64.
55. Mohan J, Gandhi AA, Bhavya BC, et al. Caspase-2 triggers Bax-Bak-dependent and -independent cell death in colon cancer cells treated with resveratrol. J Biol Chem 2006; 281: 17599-611.
56. Aziz MH, Nihal M, Fu VX, et al. Resveratrol-caused apoptosis ofhuman prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 2006; 5: 1335-41.
57. Roy P, Kalra N, Prasad S, et al. Chemopreventive potential ofresveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res 2009; 26: 211-7.
58. Clément MV, Hirpara JL, Chawdhury SH, et al. Chemopreventiveagent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 1998; 92: 996-1002.
59. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms ofresveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen insensitive prostate cancer cells. Mol Cell Biochem 2007; 304: 273-85.
60. Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3,4',5-trihydroxystilbene): molecular mechanisms and therapeutic potential. J Mol Signal 2007; 2: 7.
61. Zhang S, Cao HJ, Davis FB, et al. Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer 2004; 91: 178-85.
62. Tang HY, Shih A, Cao HJ, et al Resveratrol-induced cyclooxy-genase-2 facilitates p53-dependent apoptosis in human breast cancer cells. Mol Cancer Ther 2006; 5: 2034-42.
63. George J, Singh M, Srivastava AK, et al. Resveratrol and black teapolyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One 2011; 6: e23395.
64. Park JW, Choi YJ, Suh SI, et al. Bcl-2 overexpression attenuatesresveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 2001; 22: 1633-9.
65. Alkhalaf M, El-Mowafy A, Renno W, et al. Resveratrol-inducedapoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway. Arch Med Res 2008; 39: 162-8.
66. Chan JY, Phoo MS, Clement MV, et al. Resveratrol displays con-verse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther 2008: 7: 1305-12.
67. Hayashibara T, Yamada Y, Nakayama S, et al. Resveratrol inducesdownregulation in survivin expression and apoptosis in HTLV-1 infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer 2002; 44: 193-201.
68. Aziz MH, Afaq F, Ahmad N. Prevention of ultraviolet-B radiationdamage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem Photobiol 2005; 81: 25-31.
69. Pozo-Guisado E, Merino JM, Mulero-Navarro S, et al. Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kappaB. Int J Cancer 2005; 115: 74-84.
70. Pöhland T, Wagner S, Mahyar-Roemer M, et al. Bax and Bak arethe critical complementary effectors of colorectal cancer cell apoptosis by chemopreventive resveratrol. Anticancer Drugs 2006; 17: 471-8.
71. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhib-its cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273: 21875-82.
72. Szewczuk LM, Forti L, Stivala LA, et al. Resveratrol is a peroxi-dase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem 2004; 279: 22727-37.
73. Zykova TA, Zhu F, Zhai X, et al. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 2008; 47: 797-805.
74. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is amechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000; 67: 3103-012.
75. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydro carbon receptor. Cancer Res 1998; 58: 5707-12.
76. Lee JE, Safe S. Involvement of a post-transcriptional mechanism inthe inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol 2001; 62: 1113-24.
77. Chen ZH, Hurh YJ, Na HK, et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004; 25: 2005-13.
78. Spanier G, Xu H, Xia N, et al. Resveratrol reduces endothelialoxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 2009; 60: 111-6.
79. Floreani M, Napoli E, Quintieri L, et al. Oral administration oftrans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci 2003; 72: 2741-50.
80. Reybier K, Perio P, Ferry G, et al. Insights into the redox cycle ofhuman quinone reductase 2. Free Radic Res 2011; 45: 1184-95.
81. Ulrich S, Huwiler A, Loitsch S, et al. De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochem Pharmacol 2007: 74: 281-9.
82. Trincheri NF, Nicotra G, Follo C, et al. Resveratrol induces celldeath in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 2007; 28: 922-31.
83. Cao Z, Fang J, Xia C, et al. Trans-3,4,5'-Trihydroxystibene inhibitshypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res 2004; 10: 5253-63.
84. Wu H, Liang X, Fang Y, et al. Resveratrol inhibits hypoxia-induced metastasis potential enhancement by restricting hypoxia induced factor-1 alpha expression in colon carcinoma cells. Biomed Pharmacother 2008; 62: 613-21.
85. Smith TG, Robbins PA, Ratcliffe PJ. The human side of hypoxia-inducible factor. Br J Haematol 2008; 141: 325-34.
86. Della Ragione F, Cucciolla V, Criniti V, et al. P21Cip1 gene ex-pression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem 2003; 278: 23360-8.
87. Guarente L. Diverse and dynamic functions of the Sir silencingcomplex. Nat Genet 1999; 23: 281-5.
88. Zhao K, Harshaw R, Chai X, et al. Structural basis for nicotina-mide cleavage and ADP-ribose transfer by NAD+-dependent Sir2 histone/protein deacetylases. Proc Natl Acad Sci USA 2004; 101: 8563-8568.
89. Yamamoto H, Schoonjans K and Auwerx J. Sirtuin Functions inHealth and Disease. Mol Endocrinol 2007; 21: 1745-55.
90. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425: 191-6.
91. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves healthand survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
92. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8: 157-68.
93. Miller RA, Harrison DE, Astle CM, et al. Rapamycin, but notresveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011; 66: 191-201.
94. Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activa-tor of SIRT1 enzyme activity. Chem Biol Drug Des 2009; 74: 619-24.
95. Dai H, Kustigian L, Carney D, et al. SIRT1 activation by smallmolecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 2010; 285: 32695-703.
96. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol im-proves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
97. Park SJ, Ahmad F, Philp A, et al. Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases. Cell 2012; 148: 421-33.
98. Price NL, Gomes AP, Ling AJ, et al. SIRT1 is required for AMPKactivation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 2012; 15: 675-90.
99. Vang O, Ahmad N, Baile CA, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011; 6: e19881.
100. la Porte C, Voduc N, Zhang G, et al. Steady-State pharmacokinet-ics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clin Pharmacokinet 2010; 49: 449-54.
101. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic andsafety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009; 53: 7-15.
102. Wong RH, Howe PR, Buckley JD, et al. Acute resveratrol supple-mentation improves flow-mediated dilatation in overweight/ obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011; 21: 851-6.
103. Elliott PJ, Walpole S, Morelli L, et al. Resveratrol/SRT501. SirtuinSIRT1 activator, Treatment of type 2 diabetes. Drugs Fut 2009; 34: 291-5.
104. Soleas GJ, Yan J, Goldberg DM. Measurement of trans-resveratrol,(1)-catechin, and quercetin in rat and human blood and urine by gas chromatography with mass selective detection. Methods Enzymol 2001; 335: 130-45.
105. Soleas GJ, Yan J, Goldberg DM. Ultrasensitive assay for threepolyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 2001; 757: 161-72.
106. Walle T, Hsieh F, DeLegge MH, et al. High absorption but verylow bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-82.
107. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventós RM, et al. Highurinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol Res 2012; 65: 615-20.
108. Tomé-Carneiro J, Gonzálvez M, Larrosa M, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 2012; 110: 356-63.
109. Timmers S, Konings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-22.
110. Brown VA, Patel KR, Viskaduraki M, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers:safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 2010; 70: 9003-11.
111. Patel KR, Brown VA, Jones DJ, et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. CancerRes 2010; 70: 7392-9.
112. Boocock DJ, Faust GE, Patel KR. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential can-cer chemopreventive agent. Canc Epidemiol Biomarkers Prev 2007; 16: 1246-52.
113. Nguyen AV, Martinez M, Stamos MJ, et al. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratroland grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Canc Manag Res 2009; 1: 25-37.
114. Howells LM, Berry DP, Elliott PJ, et al. Phase I randomised dou-ble-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases safety, pharmacokinetics and pharmacodynamics. Cancer Prev Res 2011; 4: 1419-25.
115. Calabrese EJ, Mattson MP, Calabrese V. (2010) Resveratrol commonly displays hormesis: Occurrence and biomedical significante, Hum Exp Toxicol 29: 980-1015.
116. Calabrese EJ, Baldwin LA, and Holland CD Hormesis: a highly generalizable and reproducible phenomenon with important impli-cations for risk assessment. Risk Anal 1999; 19: 261-81.
117. Talalay P, Dinkova-Kostova AT, Holtzclaw WD. Importance of phase 2 gene regulation in protection against electrophile and reac-tive oxygen toxicity and carcinogenesis. Adv Enzyme Regul 2003; 43: 121-34.
118. Lithgow GJ, Walker GA. Stress resistance as a determinate of C. elegans lifespan. Mech Ageing Dev 2002; 123: 765-71.
119. McElwee JJ, Schuster E, Blanc E Piper, et al. Evolutionary conservation of regulated longevity assurance mechanisms. GenomeBiol 2007; 8: R132.
120. Clancy DJ, Gems D, Harshman LG, et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science 2001; 292: 104-6.
121. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist forthe estrogen receptor. Proc Natl Acad Sci U S A. 1997; 94: 14138-43.
122. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of humanbreast cancer cells. J Cell Physiol 1999; 179: 297-304.
123. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha andbeta. Endocrinology 2000; 141: 3657-67.
124. Vyas S, Asmerom Y, De Leon DD. Resveratrol regulates insulin like growth factor-II in breast cancer cells. Endocrinology 2005;146: 4224-33.
125. Vyas S, Asmerom Y, De Leon DD. Insulin-like growth factor II mediates resveratrol stimulatory effect on cathepsin D in breastcancer cells. Growth Factors 2006; 24: 79-87.
126. Wietzke JA, Welsh J. Phytoestrogen regulation of a vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in humanbreast cancer cells. J Ster Biochem Mol Biol. 2003; 84: 149-57.
127. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer inrelation to diet, physical activity, and body size in blacks, whites, and asians in the United States and Canada. J Natl Cancer Inst 1995; 879: 652-61.
128. Ratan HL, Steward WP, Gescher AJ, Mellon JK. Resveratrol-a prostate cancer chemopreventive agent? Urol Oncol 2002; 6: 223-7.
129. Thorne J, Campbell MJ. The vitamin D receptor in cancer. Proc Nutr Soc 2008; 67: 115-27.
130. Parnes HL, House MG, Kagan J, Kausal DJ, Lieberman RM. Prostate cancer chemoprevention agent development: The national cancer institute, division of cancer prevention portfolio. J Urol 2004; 171: 2 Pt 2): S68, 74; discussion S75.
131. Hsieh T-C, Wu JM. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancercell lines. Exp Cell Res 1999; 249: 109-15.
132. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: Molecular basis, open questions and promises. J Nutr Biochem 2005; 168: 449-66.
133. Mitchell SH, Zhu W and Young CYF. Resveratrol inhibits theexpression and function of the androgen receptor in LNCAP prostate cancer cells. Cancer Res 1999; 59: 5892-5.
134. Shi WF, Leong M, Cho E, et al. Repressive Effects of Resveratrolon Androgen Receptor Transcriptional Activity PLoS ONE 2009; 4: e7398.
135. Hsieh TC, Wu JM. Grape-derived chemopreventive agent resvera-trol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 2000; 20: 225-8.
136. Benitez DA, Pozo-Guisado E, Clementi M, Castellon E, Fernan-dez-Salguero PM. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: Modulation of the phosphoinositide 3-kinase pathway. Br J Cancer 2007; 96: 1595-604.
137. Yuan H, Pan Y, Young CY. Overexpression of c-jun induced byquercetin and resverol inhibits the expression and function of the androgen receptor in human prostate cancer cells. Cancer Lett 2004; 213: 155-63.
138. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expres-sion and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 1999; 59: 5892-5.
139. Wang TT, Hudson TS, Wang TC, et al. Differential effects ofresveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008; 29: 2001-10.
140. Jones SB, DePrimo SE, Whitfield ML, Brooks JD. Resveratrol-induced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2005; 14: 596-604.
141. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004; 592: 214-25.
142. Harada N, Murata Y, Yamaji R, et al. Resveratrol down-regulatesthe androgen receptor at the post-translational level in prostate cancer cells. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 556-60.
143. Lekli I, Szabo G, Juhasz B, et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 2008; 294: H859-66.
144. Thirunavukkarasu M, Penumathsa SV, Koneru S, et al. Resveratrolalleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007; 43: 720-9.
145. Dudley J, Das S, Mukherjee S, Das DK. Resveratrol, a uniquephytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem. 2009; 20: 443-452.
146. Tseng PC, Hou SM, Chen RJ, et al. Resveratrol promotes os-teogenesis of human mesenchymal stem cells by upregulating RUNX2 gene expression via the SIRT1/FOXO3A axis. J Bone Miner Res 2011; 26: 2552-63.
147. Dey A, Guha P, Chattopadhyay S, Bandyopadhyay SK. Biphasicactivity of resveratrol on indomethacin-induced gastric ulcers. Biochem Biophys Res Comm 2009; 381: 90-5.